Atossa Therapeutics (ATOS) news
Recent news
Atossa Therapeutics - CVR holders entitled to 25% of net proceeds, $50 mln aggregate cap
AInvest Wire · 6d agoAtossa Therapeutics executes contingent value rights agreement providing shareholders participation in potential priority review voucher value
Atossa Therapeutics Inc. has entered into a contingent value rights agreement, granting shareholders the opportunity to participate in the potential value of a priority review voucher (PRV) associated with the company’s drug development programs. The agreement is structured to provide shareholders…
AInvest Wire · 6d agoAtossa Therapeutics: Ascendant Capital Markets raises target price to $25 from $24
Ascendant Capital Markets has raised its 12-month price target for Atossa Therapeutics Inc (ATOS) to $25 from $24, reflecting a modest upward revision in its valuation outlook for the biopharmaceutical company. The adjustment follows a reassessment of Atossa’s strategic initiatives and market…
AInvest Wire · Oct 1, 2026Atossa Therapeutics - Expects to file CVR agreement with SEC once executed
AInvest Wire · Sep 29, 2026Atossa Therapeutics - CVRS entitle holders to 25% of net proceeds, capped at $50 mln
AInvest Wire · Sep 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.